AMC
RNAC icon

Asset Management Corp’s Cartesian Therapeutics RNAC Stock Holding History

Asset Management Corp’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$107K – 203
2020
Q4 		$107K Buy
+1,000
New +$86.7K 0.06% 165

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Asset Management Corp's RNAC Position: Q1 2021 in Review

Asset Management Corp sold out of Cartesian Therapeutics (RNAC) in Q1 2021, closing a stake of 1,000 shares — an estimated $107K sold.

Asset Management Corp first reported a position in RNAC in Q4 2020 and held it in 1 quarter. The position peaked at $107K in Q4 2020. 98 funds tracked by Wall St. Rank hold RNAC as of Q1 2021.

  • Asset Management Corp reported no remaining Cartesian Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Asset Management Corp sold 1,000 Cartesian Therapeutics shares in Q1 2021, an estimated $107K.
  • Asset Management Corp first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 1 quarter.
  • Asset Management Corp's Cartesian Therapeutics position peaked at $107K in Q4 2020.
  • 98 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2021.

Based on Asset Management Corp's 13F filing for Q1 2021, filed 4 May 2021.